Status:
ACTIVE_NOT_RECRUITING
Ultra-low-dose Chest CT for HHT
Lead Sponsor:
Mayo Clinic
Conditions:
Hereditary Hemorrhagic Telangiectasia
Eligibility:
All Genders
1-17 years
Brief Summary
This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achie...
Eligibility Criteria
Inclusion
- Ages 1 to 17 years
- Diagnosed with positive HHT causing mutations or based on Curacao criteria
Exclusion
- Acute respiratory distress
- Unstable cardiovascular status
- Pneumothorax, hemoptysis
- Pulmonary edema
- Pulmonary emboli
- Fractured ribs or other chest trauma
- Recent bronchoscopy
- Lung transplantation
Key Trial Info
Start Date :
April 21 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04874558
Start Date
April 21 2021
End Date
December 31 2025
Last Update
July 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905